Dr. Mira Baron

Internal Medicine
Palm Beach Research Center
2277 Palm Beach Lakes Blvd, 
West Palm Beach, FL 
Palm Beach Research Center
2277 Palm Beach Lakes Blvd, 
West Palm Beach, FL 

Overview

Mira Baron is a primary care provider, practicing in Internal Medicine in West Palm Beach, Florida.

Her clinical expertise encompasses Migraine with Brainstem Aura, Familial Hemiplegic Migraine, Migraine, and Parainfluenza.

She is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 12 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Palm Beach Research Center
2277 Palm Beach Lakes Blvd, West Palm Beach, FL 33409

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
Enrollment Status: Completed
Publish Date: March 28, 2024
Intervention Type: Drug
Study Drug: X0002
Study Phase: Phase 3
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Combination product, Biological
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.
A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Combination product
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
View 9 Less Clinical Trials

7 Total Publications

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
Journal: Science (New York, N.Y.)
Published: November 23, 2021
Similar Doctors
Expertise in
34
conditions
Dr. David Milbauer
Internal Medicine
Expertise in
34
conditions
Dr. David Milbauer
Internal Medicine

Dr. David Milbauer M.D.

6894 Lake Worth Rd Ste 104, 
Lake Worth, FL 
 (9.2 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Milbauer is a primary care provider, practicing in Internal Medicine in Lake Worth, Florida. Dr. Milbauer is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Nephrosclerosis, Renovascular Hypertension, Hypertensive Heart Disease, Pacemaker Implantation, and Endoscopy.

Expertise in
62
conditions
Dr. James Chong
Internal Medicine
Expertise in
62
conditions
Dr. James Chong
Internal Medicine

Office

4675 Linton Blvd Ste 202, 
Delray Beach, FL 
 (17.6 miles away)
561-495-5700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Chong is an Internal Medicine provider practicing medicine in Delray Beach, Florida. Dr. Chong is highly rated in 62 conditions, according to our data. His clinical expertise encompasses Angiodysplasia of the Colon, Barrett Esophagus, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Gastrectomy.

Expertise in
8
conditions
Dr. Seth Baum
Internal Medicine
Expertise in
8
conditions
Dr. Seth Baum
Internal Medicine

Office

7900 Glades Rd Ste 400, 
Boca Raton, FL 
 (23.0 miles away)
561-488-5535
Languages Spoken:
English
See accepted insurances

Seth Baum is an Internal Medicine provider practicing medicine in Boca Raton, Florida. Dr. Baum is highly rated in 8 conditions, according to our data. His clinical expertise encompasses High Cholesterol, Defective Apolipoprotein B-100, Homozygous Familial Hypercholesterolemia (HoFH), and Heterozygous Familial Hypercholesterolemia (HeFH).

Frequently Asked Questions about Dr. Mira Baron

How do I make an appointment with Dr. Mira Baron?

You can book an appointment with Dr. Mira Baron by calling their office at 561-689-0606. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mira Baron a top-rated expert for Migraine with Brainstem Aura?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mira Baron is classified as an Experienced expert for Migraine with Brainstem Aura, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mira Baron specialize in?

While Dr. Mira Baron is a Internal Medicine, they have specific expertise in Migraine with Brainstem Aura, Familial Hemiplegic Migraine, and Migraine. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Mira Baron participate in research or clinical trials?

Yes. Dr. Mira Baron has published 7 articles and abstracts on conditions like Migraine with Brainstem Aura. You can view a list of Dr. Mira Baron's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mira Baron accept my insurance?

Dr. Mira Baron accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 561-689-0606 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baron's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile